Drug Trial Radar · NCT01761266
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Apr 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
954
Actual
Start
Mar 1, 2013
Primary completion
Nov 13, 2016
Study completion Mar 10, 2021
Sponsor
- Lead sponsor
- Eisai LimitedEisai
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jan 4, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
LenvatinibDrug
12 mg (or 8 mg) once daily (QD) oral dosing.
SorafenibDrug
400 mg twice daily (BID) oral dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From date of randomization until date of death from any cause (approximately up to 3.8 years)
Locations
186 sites in 21 countries. Site status is shown where the registry gives one.
Facility # 1
Los Angeles, California
Facility # 1
Sacramento, California
Facility # 1
San Francisco, California
Facility # 1
Washington D.C., District of Columbia
Facility # 1
Tampa, Florida
Facility # 1
Duluth, Georgia
Facility # 1
Lawrenceville, Georgia
Facility # 1
Baltimore, Maryland
Facility # 1
Detroit, Michigan
Facility # 1
Kansas City, Missouri
Facility # 1
St Louis, Missouri
Facility # 1
East Orange, New Jersey
Facility # 1
Brooklyn, New York
Facility # 1
Lake Success, New York
Facility # 1
New York, New York
Facility # 1
Charlotte, North Carolina
Facility # 1
Durham, North Carolina
Facility # 1
Portland, Oregon
Facility # 1
Austin, Texas
Facility # 1
Lubbock, Texas
Facility # 1
Seattle, Washington
Facility # 1
Camperdown, New South Wales, Australia
Facility # 1
Wentworthville, New South Wales, Australia
Facility # 1
Woolloongabba, Queensland, Australia
Facility # 1
Fitzroy, Victoria, Australia
Facility # 1
Melbourne, Victoria, Australia
Facility # 2
Melbourne, Victoria, Australia
Facility # 1
Nedlands, Western Australia, Australia
Facility # 1
Brussels, Belgium
Facility # 1
Edegem, Belgium
Facility # 1
Liège, Belgium
Facility # 1
Ottawa, Ontario, Canada
Facility # 1
Hefei, Anhui, China
Facility # 1
Beijing, Beijing Municipality, China
Facility # 2
Beijing, Beijing Municipality, China
Facility # 3
Beijing, Beijing Municipality, China
Facility # 1
Chongqing, Chongqing Municipality, China
Facility # 1
Fuzhou, Fujian, China
Facility # 2
Fuzhou, Fujian, China
Facility # 1
Guangzhou, Guangdong, China
Showing 40 of 186 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.